title: [Drug therapy for ulcerative colitis: salazosulfapyridine and 5-ASA].
abstract: Aminosalicylates have a wide range of anti-inflammatory and immunomodulatory effects. Oral salazosulfapyridine (SASP) and 5-aminosalicylic acid (5-ASA) are the 'first-line' therapy for induction of remission in mild to moderate active ulcerative colitis (UC). SASP, which is consisted of 5-ASA and sulfapyridine, has greater incidence of side effects. 5-ASA is a therapeutically active compound, while sulfapyridine is related to adverse effects. For this reason, 5-ASA formulas exclusive of sulfapyridine were developed and they enabled higher dose of 5-ASA administration without adverse effects. Topical treatment by 5-ASA enema or SASP suppository should be considered for the treatment of proctitis or distal type of UC. Oral aminosalicylate therapy is also effective for the maintenance of remission in UC. Therefore, aminosalicylates are key drugs for the treatment of UC.
authors.affiliation: Department of Medicine and Clinical Sciences, Graduate School of Medical Sciences, Kyushu University.
authors.forename: Yukihiko
authors.initials: Y
authors.lastname: Jo
authors.forename: Takayuki
authors.initials: T
authors.lastname: Matsumoto
authors.forename: Mitsuo
authors.initials: M
authors.lastname: Iida
mesh_terms: D000284:Administration, Oral; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D004334:Drug Administration Schedule; D004733:Enema; D006801:Humans; D019804:Mesalamine / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry; D012460:Sulfasalazine / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry; D013488:Suppositories
chemical_list: D013488:Suppositories; D012460:Sulfasalazine; D019804:Mesalamine